血清CYFRA21-1的检测在实体恶性肿瘤诊断和预后判断中的价值  

Clinical Analysis of CYFRA21-1 in Diagnosis and Assesing Prognosis in Carcinoma Patients

作　　者：吴培[1] 吴复平[1] 邹继红[1] 顾晓怡[1] 

机构地区：[1]南京铁道医学院附属医院,江苏南京210009

出　　处：《南京铁道医学院学报》2000年第4期262-264,共3页Journal of Nanjing Railway Medical College

摘　　要：目的 :研究CYFRA2 1 1对来源于上皮细胞的实体恶性肿瘤诊断、分期及预后判断的临床意义。方法 :采用免疫放射分析法检测 35例正常人、30例非肿瘤患者、5 3例恶性肿瘤患者的血清CYFRA2 1 1水平。结果 :正常人组及非肿瘤患者组检测阳性率明显低于恶性肿瘤组 (P <0 .0 0 1)。CYFRA2 1 1在来源于上皮细胞的实体恶性肿瘤中均有表达 :0～Ⅰ期者为 (3 .86± 0 .86 ) μg·L-1,Ⅱ～Ⅲa期者为 (2 8.33± 18.92 ) μg·L-1,Ⅲb～Ⅳ期者为 (190 .2 3± 75 .94) μg·L-1。随病情的发展 ,血清中CYFRA2 1 1含量明显增加 (P <0 .0 1)。结论 :血清CYFRA2 1 1的含量可作为对来源于上皮细胞的实体恶性肿瘤进行诊断。Objective The purpose of the study was to evaluate the significance of CYFRA21 1 in diagnosis,grading and assessing prognosis of malignant carcinoma developing from the epithelial cell.Methods The serum CYFRA21 1 levels were detected by immunoradiometric assay in 118 persons including 35 normal subjects,30 non carcinoma cases and 53 malignant carcinoma cases.Results The positive rates of CYFRA21 1 were 0 in normal control group,6.00% in non carcinoma group and 64.40% in malignant carcinoma group.The positive rate in malignant carcinoma group was significantly higher than that in normal control group and non carcinoma group( P <0.001).The expression of CYFRA21 1 was found in all cases of malignant carcinoma developing from the epithelial cell.The CYFRA21 1 levels were (3.86±0.86)μg·L -1 in 0～Ⅰ stage,(28.33±18.92)μg·L -1 in Ⅱ～Ⅲ a stage and (190.23±75.94)μg·L -1 in Ⅲ b～Ⅳ stage.It's value was increasing as the stage was developing( P <0.01).Conclusion Determination of serum CYFRA21 1 may serve as an objective index for diagnosis,gra^ding and assessing prognosis of malignant carcinoma that takes origin from the epithelial cells.

关 键 词：CYFRA21-1 恶性肿瘤 上皮细胞 角蛋白 诊断 

分 类 号：R730.4[医药卫生—肿瘤]